Primary Hyperoxaluria Type 1: A Rare Metabolic Disease Driven by Hepatic Enzyme Deficiency
Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disorder caused by loss-of-function mutations in the AGXT gene, which encodes alanine-glyoxylate aminotransferase (AGT) — a liver-specific peroxisomal enzyme responsible for converting glyoxylate to glycine. Without functional AGT, glyoxylate accumulates and is instead oxidised to oxalate by lactate dehydrogenase A (LDHA) and other enzymes, causing systemic oxalate overproduction. The resulting hyperoxaluria leads to recurrent nephrolithiasis, nephrocalcinosis, and ultimately end-stage renal disease (ESRD) in a significant proportion of patients.
PH1 is the most common and most severe of the three primary hyperoxaluria subtypes. PH2 arises from mutations in GRHPR (encoding glyoxylate reductase/hydroxypyruvate reductase), while PH3 involves mutations in HOGA1 (encoding 4-hydroxy-2-oxoglutarate aldolase). All three subtypes share the downstream consequence of excess oxalate production, but PH1 carries the greatest burden of systemic oxalate deposition — a condition known as oxalosis — when kidney function declines. According to NIH rare disease databases, the estimated prevalence of PH1 is approximately 1–3 cases per million population in Europe and North America, though it is likely underdiagnosed.
The AGXT gene encodes alanine-glyoxylate aminotransferase (AGT), a peroxisomal enzyme expressed exclusively in hepatocytes. In PH1, over 200 pathogenic variants in AGXT have been identified. Loss of AGT function means glyoxylate cannot be detoxified to glycine; instead it is converted to oxalate by LDHA and to glycolaldehyde by other routes. This hepatic metabolic bottleneck is the rationale for both liver transplantation and RNA-interference therapies targeting upstream or downstream enzymes in the glyoxylate pathway.
Prior to the approval of RNA-interference therapies, management of PH1 was largely supportive — high fluid intake, pyridoxine supplementation (effective only in the ~30% of patients with pyridoxine-responsive variants), and ultimately combined liver-kidney transplantation to correct the enzymatic defect and replace oxalate-damaged kidneys. The approval of lumasiran (Oxlumo) by Alnylam Pharmaceuticals in November 2020 marked the first RNAi therapy for PH1, validating the hepatic RNAi approach. Nedosiran’s subsequent approval in September 2023 introduced a mechanistically distinct but complementary siRNA option to the same disease space.
Primary hyperoxaluria type 1 (PH1) is caused by loss-of-function mutations in the AGXT gene, which encodes the hepatic enzyme alanine-glyoxylate aminotransferase (AGT). Without functional AGT, glyoxylate accumulates and is converted to oxalate by LDHA, leading to hyperoxaluria, nephrolithiasis, and end-stage renal disease.
How Nedosiran Targets LDHA to Reduce Oxalate at the Final Enzymatic Step
Nedosiran reduces hepatic oxalate production by silencing LDHA — the gene encoding lactate dehydrogenase A — which catalyses the terminal conversion of glyoxylate to oxalate in hepatocytes. This distinguishes nedosiran from lumasiran, which acts further upstream by silencing HAO1 (hydroxyacid oxidase 1, also known as glycolate oxidase) to reduce glyoxylate generation. By targeting the final enzymatic step, nedosiran’s mechanism is theoretically applicable regardless of which upstream enzyme is deficient — making it potentially active in PH1, PH2, and PH3.
Nedosiran uses Dicerna’s proprietary GalXC (GalNAc-conjugated) RNAi delivery platform. GalNAc (N-acetylgalactosamine) conjugation enables selective uptake into hepatocytes via the asialoglycoprotein receptor (ASGPR), which is highly expressed on the surface of liver parenchymal cells. This targeted delivery mechanism is shared with lumasiran and several other approved GalNAc-siRNA drugs including inclisiran (for hypercholesterolaemia) and givosiran (for acute hepatic porphyria). The GalXC platform uses a tetraloop-based siRNA structure that Dicerna developed as an alternative to Alnylam’s Enhanced Stabilisation Chemistry (ESC) platform, enabling differentiated intellectual property.
Nedosiran is administered as a once-monthly subcutaneous injection. The dosing regimen approved by the FDA is weight-based: patients weighing 10 kg to less than 20 kg receive 50 mg monthly; those 20 kg to less than 40 kg receive 100 mg monthly; and patients 40 kg or more receive 160 mg monthly. Lumasiran, by contrast, uses a loading-dose regimen of three monthly injections followed by quarterly maintenance dosing — a schedule some prescribers view as advantageous for adherence. The monthly versus quarterly dosing difference is a clinically meaningful competitive variable in a patient population that already faces significant treatment burden.
Nedosiran (Rivfloza) is a GalNAc-conjugated siRNA that silences LDHA (lactate dehydrogenase A) in hepatocytes, blocking the final enzymatic conversion of glyoxylate to oxalate. Its mechanism of action is theoretically applicable to all three subtypes of primary hyperoxaluria (PH1, PH2, and PH3) because all three subtypes ultimately produce excess oxalate via the glyoxylate pathway.
The GalXC platform’s tetraloop architecture is protected by a distinct IP estate from Dicerna (now Novo Nordisk). This structural differentiation was strategically important: Alnylam Pharmaceuticals has historically asserted broad IP around its GalNAc-siRNA conjugation chemistry, and Dicerna’s GalXC design was developed in part to circumvent those claims. Patent disputes between Alnylam and Dicerna were settled in 2021 as part of a cross-licensing agreement, which cleared the path for nedosiran’s commercial development without ongoing litigation risk — a resolution that significantly de-risked Novo Nordisk’s subsequent acquisition.
PHYOX Trials: The Clinical Evidence That Secured FDA Approval
The FDA approval of nedosiran on September 29, 2023, was supported by a clinical development programme spanning multiple PHYOX trials, with the pivotal PHYOX2 Phase 3 randomised, double-blind, placebo-controlled trial providing the primary efficacy evidence. PHYOX2 enrolled adult and paediatric patients (aged 9 years and older) with PH1 and relatively preserved kidney function (estimated glomerular filtration rate ≥30 mL/min/1.73 m²), and demonstrated statistically significant reductions in 24-hour urinary oxalate excretion compared with placebo.
“Nedosiran’s PHYOX2 trial demonstrated statistically significant reductions in 24-hour urinary oxalate excretion in PH1 patients — establishing the LDHA-silencing approach as clinically validated in a disease where kidney failure had been the historical endpoint.”
The PHYOX programme included several complementary studies. PHYOX1 was a Phase 1 single-ascending-dose study in healthy volunteers and PH1 patients that established the pharmacokinetic and pharmacodynamic profile of nedosiran. PHYOX3 is an ongoing open-label extension study providing long-term safety and durability-of-effect data for patients completing PHYOX2. PHYOX8 was a dedicated paediatric study in patients aged 9 to 17 years, the data from which supported the paediatric label extension.
A key eligibility criterion in PHYOX2 was relatively preserved kidney function — specifically an eGFR of at least 30 mL/min/1.73 m². This restriction reflects the hepatic delivery mechanism of GalNAc-siRNA drugs: as kidney function deteriorates, the clinical benefit of reducing urinary oxalate becomes less relevant to immediate renal outcomes, and the safety profile in advanced CKD is less well characterised. Lumasiran carries a similar label restriction, meaning both approved RNAi therapies for PH1 are currently indicated for patients who have not yet progressed to dialysis or end-stage disease — a limitation that underscores the unmet need for therapies effective in more advanced disease stages.
Track nedosiran’s clinical programme, patent filings, and competitive pipeline in real time with PatSnap Eureka.
Explore Drug Intelligence in PatSnap Eureka →The FDA granted nedosiran Orphan Drug Designation, Rare Paediatric Disease designation, and Breakthrough Therapy designation — the last of which reflects the agency’s assessment that preliminary clinical evidence indicated substantial improvement over available therapies. Breakthrough designation accelerates development through more intensive FDA guidance and rolling review. The Rare Paediatric Disease designation also triggered a Priority Review Voucher (PRV) upon approval — a transferable regulatory asset that Novo Nordisk could sell to another pharmaceutical company to accelerate a separate drug’s review, representing a financial benefit estimated in recent PRV transactions at $100–150 million.
The FDA granted nedosiran Breakthrough Therapy designation, Orphan Drug Designation, and Rare Paediatric Disease designation. Upon FDA approval on September 29, 2023, Novo Nordisk received a Priority Review Voucher (PRV) under the Rare Paediatric Disease programme — a transferable regulatory asset with estimated market value of $100–150 million based on recent PRV transactions.
GalNAc-siRNA Competition: Nedosiran vs. Lumasiran in the PH1 Landscape
Nedosiran and lumasiran are both GalNAc-conjugated siRNAs approved for PH1, but they differ in target gene, dosing frequency, patient age eligibility, and intellectual property lineage — differences that are likely to shape prescribing decisions and payer negotiations in a disease with a very small patient population. Lumasiran (Oxlumo) was approved by the FDA in November 2020 and by the EMA in November 2020, giving it a three-year head start in market penetration. It is approved for all ages, including infants under 6 months, whereas nedosiran’s current label covers patients aged 9 years and older.
Lumasiran uses a loading regimen of three monthly injections followed by quarterly maintenance dosing, while nedosiran requires monthly subcutaneous injections throughout treatment. In a rare disease with a small, closely monitored patient population, the quarterly maintenance schedule of lumasiran may offer a practical adherence advantage — though nedosiran’s monthly regimen allows more frequent dose-response monitoring and potentially faster dose adjustments.
The mechanistic distinction carries clinical implications beyond PH1. Because lumasiran targets HAO1 — an enzyme specific to the glycolate oxidase step — its efficacy is most directly applicable to PH1, where the upstream glyoxylate excess is the primary driver. Nedosiran’s LDHA target is positioned downstream of all three PH genotypes’ primary enzymatic defects. Clinical trials of nedosiran in PH2 and PH3 patients have been conducted under the PHYOX programme, and preliminary data suggest oxalate-lowering activity in these subtypes as well. If nedosiran receives label expansions for PH2 and PH3, it would be the only approved pharmacological therapy for those rarer subtypes, substantially expanding its addressable patient population.
From a payer and health technology assessment (HTA) perspective, the competition between two approved siRNAs in an ultra-rare disease is unusual and creates pricing pressure. Both drugs are priced at levels typical of orphan biologics — annual treatment costs in the range of hundreds of thousands of dollars — and payers in markets with comparative effectiveness requirements (such as NICE in the UK and G-BA in Germany) will scrutinise head-to-head data that does not yet exist. The absence of a direct comparative trial between nedosiran and lumasiran means that prescribing decisions in PH1 currently rely on indirect comparisons, clinician familiarity, and patient-specific factors such as age and dosing preference.
Map the full competitive landscape for GalNAc-siRNA rare disease drugs with PatSnap Eureka’s drug intelligence tools.
Search GalNAc-siRNA Patents in PatSnap Eureka →Novo Nordisk’s $3.3 Billion Acquisition of Dicerna and the GalXC Platform
Novo Nordisk acquired Dicerna Pharmaceuticals in December 2021 for approximately $3.3 billion — a transaction that brought the GalXC RNAi platform, nedosiran, and a broader pipeline of cardiometabolic and hepatic RNAi programmes under Novo Nordisk’s ownership. The acquisition price represented a substantial premium to Dicerna’s pre-announcement market capitalisation, reflecting the strategic value Novo Nordisk assigned to GalXC as a proprietary delivery technology with applications beyond rare disease.
For Novo Nordisk, the Dicerna acquisition was part of a broader strategic pivot toward RNA-based medicines and precision metabolic therapies. Novo Nordisk had previously invested in RNA therapeutics through its partnership with Alnylam Pharmaceuticals (which included rights to fitusiran, an RNAi therapy for haemophilia), and the Dicerna acquisition gave it an independent, fully owned RNAi platform. The GalXC tetraloop structure — Dicerna’s core IP — enables efficient RISC loading and potent gene silencing at lower doses than some first-generation siRNA chemistries, according to published preclinical data. According to Nature reviews of GalNAc-siRNA chemistry, the tetraloop scaffold provides enhanced nuclease resistance and improved thermal stability compared with canonical duplex siRNA structures.
GalXC is Dicerna Pharmaceuticals’ proprietary GalNAc-conjugated RNAi delivery platform. It uses a tetraloop-based siRNA structure in which the sense and antisense strands are connected by a loop at one end, creating a more compact and nuclease-resistant molecule than linear duplex siRNA. GalNAc conjugation at the 3′ end of the sense strand enables selective uptake into hepatocytes via the ASGPR receptor. The GalXC architecture is protected by patents distinct from Alnylam’s ESC-GalNAc platform, and a cross-licensing agreement between Alnylam and Dicerna (settled in 2021) resolved prior IP disputes.
Beyond nedosiran, the GalXC pipeline that Novo Nordisk acquired includes programmes targeting ANGPTL3 (for hyperlipidaemia), HSD17B13 (for non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis, MASH), and PCSK9 (for cardiovascular disease). These cardiometabolic targets are strategically aligned with Novo Nordisk’s core therapeutic areas and represent a potential future revenue base that dwarfs the rare disease opportunity of nedosiran alone. The acquisition therefore represents a platform bet as much as a product bet — Novo Nordisk paid for GalXC’s versatility, not just for Rivfloza’s PH1 indication.
The Alnylam-Dicerna patent settlement, concluded in January 2021, was a prerequisite for the clean commercialisation of nedosiran and the broader GalXC pipeline. The settlement included mutual cross-licensing of certain RNAi-related patents and a resolution of all pending litigation between the two companies. For Novo Nordisk, acquiring Dicerna after this settlement eliminated the litigation overhang that had complicated Dicerna’s earlier partnership discussions. The WIPO patent database reflects the breadth of GalXC-related filings that Novo Nordisk now controls, covering the tetraloop scaffold structure, GalNAc conjugation variants, and specific target-gene applications including LDHA.
Novo Nordisk acquired Dicerna Pharmaceuticals in December 2021 for approximately $3.3 billion, gaining full ownership of the GalXC RNAi platform. The acquisition followed a January 2021 patent settlement between Dicerna and Alnylam Pharmaceuticals that resolved all IP disputes through mutual cross-licensing, eliminating litigation risk from the GalXC pipeline prior to nedosiran’s FDA approval in September 2023.
Patent Landscape and Future Pipeline: Beyond PH1
The patent landscape surrounding nedosiran and the GalXC platform reflects the layered IP strategy typical of advanced RNAi therapeutics: composition-of-matter patents covering the specific siRNA sequence and GalNAc conjugate, method-of-treatment patents for PH1 and other hyperoxaluria subtypes, platform technology patents covering the tetraloop scaffold, and formulation patents for the subcutaneous delivery vehicle. Novo Nordisk’s IP estate, built on Dicerna’s filings, spans multiple jurisdictions including the United States, European Union, Japan, and China.
Key patent families to monitor include those covering the LDHA-targeting siRNA sequences specific to nedosiran, the GalXC tetraloop architecture broadly, and the method-of-treatment claims for PH2 and PH3 — the latter being strategically important if nedosiran receives label expansions for those subtypes. The EPO register shows active prosecution of several GalXC-related applications in Europe, with examination proceedings ongoing for claims covering the tetraloop structure and hepatocyte-selective delivery. Patent expiry timelines for the core nedosiran composition-of-matter patents are expected to extend into the mid-2030s, providing a substantial exclusivity window for Rivfloza.
Looking beyond primary hyperoxaluria, the clinical and commercial logic of the GalXC platform points toward cardiometabolic indications. Novo Nordisk has disclosed GalXC-based programmes targeting ANGPTL3 for severe hypertriglyceridaemia and mixed dyslipidaemia, and HSD17B13 for MASH — both conditions with large patient populations and significant unmet need. If GalXC-based drugs succeed in these indications, the platform’s value proposition will be validated far beyond the rare disease context in which nedosiran was developed. According to data tracked by the ClinicalTrials.gov registry, multiple GalXC-based investigational drugs are currently in Phase 1 and Phase 2 studies for hepatic targets outside of primary hyperoxaluria.
For competitive intelligence professionals and IP analysts, nedosiran’s approval represents a case study in several important dynamics: the maturation of GalNAc-siRNA as a validated drug class; the role of platform IP differentiation in enabling competition within a technology category dominated by a single pioneer (Alnylam); the strategic logic of large-cap pharma acquiring biotechnology platform companies rather than licensing individual assets; and the use of regulatory designations (Breakthrough, Orphan, Rare Paediatric Disease) to compress development timelines and generate transferable financial assets (PRVs) in ultra-rare disease. PatSnap’s pharmaceutical intelligence solutions provide the patent, clinical, and regulatory data needed to monitor these dynamics in real time across the GalNAc-siRNA competitive landscape.
The broader RNAi therapeutic landscape — tracked extensively by organisations such as FDA through its approved drug database — now includes multiple GalNAc-siRNA drugs across hepatic indications, from inclisiran in cardiovascular disease to givosiran in acute hepatic porphyria and vutrisiran in transthyretin amyloidosis. Nedosiran’s approval adds to this growing class and reinforces the hepatocyte-targeting paradigm as the dominant delivery strategy for siRNA therapeutics. The competitive question for the next decade is not whether GalNAc-siRNA works — it clearly does — but which companies control the IP, manufacturing know-how, and clinical data packages needed to compete across the expanding universe of hepatic gene targets.